GlassScriptPhysician profile
Brandon K Musgrave
NPI 1619132420
$2,629.19
in general payments reported to CMS, 2019-2025
15 companies · $87.66 in 2025
The $87.66 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,381 · 2020: $262 · 2021: $86.96 · 2022: $251 · 2023: $166 · 2024: $395 · 2025: $87.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $648.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,321.05 | 2019-2023 | Xpress Ent Dilation System, Scopis Ent |
| Intersect Ent, INC. | $345.99 | 2019 | |
| Medtronic, INC. | $321.04 | 2023-2025 | Sinuva, Propel, Nuvent |
| Medtronic USA, INC. | $170.65 | 2019 | |
| Optinose US, INC. | $141.67 | 2019-2020 | |
| Aerin Medical INC. | $84.79 | 2019-2024 | |
| Neurent Medical Limited | $59.76 | 2024 | Neuromark Device, Neuromark Radiofrequency Console |
| Regeneron Healthcare Solutions, INC. | $36.40 | 2024 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $27.03 | 2025 | Neffy |
| Genzyme Corporation | $26.55 | 2025 | |
| Smith+Nephew, INC. | $21.02 | 2023 | Ent Sinus |
| Acclarent, INC | $20.51 | 2019 | |
| Inspire Medical Systems, INC. | $18.49 | 2023 | Inspire |
| Checkpoint Surgical, INC | $18.32 | 2023 | Checkpoint Stimulators |
| Alk-Abello, INC | $15.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Musgrave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.